ReviewCells2017
May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells.
Review in Cells, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- CRISPR/Cas9 and iPSC-Based Therapeutic Approaches in Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Stem Cell Interventions in the Treatment of Alzheimer's Disease.Current stem cell research & therapy · 2025Review
- Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.International journal of molecular sciences · 2024Review
- CGMP Compliant Microfluidic Transfection of Induced Pluripotent Stem Cells for CRISPR-Mediated Genome Editing.Stem cells (Dayton, Ohio) · 2023Article
- On the utilization of the induced pluripotent stem cell (iPSC) model to study substance use disorders: A scoping review protocol.PloS one · 2023Article
- Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders.International journal of molecular sciences · 2022Review
- Nanoparticles-based anti-aging treatment of Alzheimer's disease.Drug delivery · 2022Review
- Highly Efficient CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells.Current protocols · 2022Article
- [From the laboratory to the clinic in acute ischaemic stroke. In vitro and in vivo experimental models].Revista de neurologia · 2022Review
- Development of a universal antibiotic resistance screening reporter for improving efficiency of cytosine and adenine base editing.The Journal of biological chemistry · 2022Article
- A precise gene delivery approach for human induced pluripotent stem cells using Cas9 RNP complex and recombinant AAV6 donor vectors.PloS one · 2022Article
- Microfluidic processing of stem cells for autologous cell replacement.Stem cells translational medicine · 2021Review
- Recent progress in translational engineered in vitro models of the central nervous system.Brain : a journal of neurology · 2020Review
- Precise Correction of Heterozygous SHOX2 Mutations in hiPSCs Derived from Patients with Atrial Fibrillation via Genome Editing and Sib Selection.Stem cell reports · 2020Article
- Stem cell therapy for Alzheimer's disease.World journal of stem cells · 2020Review
- BEON: A Functional Fluorescence Reporter for Quantification and Enrichment of Adenine Base-Editing Activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.Neurobiology of disease · 2020Review
- Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiation.Stem cells translational medicine · 2020Article
- The future of stem cell therapies for Parkinson disease.Nature reviews. Neuroscience · 2020Review
- A transient reporter for editing enrichment (TREE) in human cells.Nucleic acids research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the decade since Yamanaka and colleagues described methods to reprogram somatic cells into a pluripotent state, human induced pluripotent stem cells (hiPSCs) have demonstrated tremendous promise in numerous disease modeling, drug discovery, and regenerative medicine applications. More recently, the development and refinement of advanced gene transduction and editing technologies have further accelerated the potential of hiPSCs. In this review, we discuss the various gene editing technologies that are being implemented with hiPSCs. Specifically, we describe the emergence of technologies including zinc-finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 that can be used to edit the genome at precise locations, and discuss the strengths and weaknesses of each of these technologies. In addition, we present the current applications of these technologies in elucidating the mechanisms of human development and disease, developing novel and effective therapeutic molecules, and engineering cell-based therapies. Finally, we discuss the emerging technological advances in targeted gene editing methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.